Jose A Vazquez1, Ahmad A Zawawi. 1. Division of Infectious Diseases, Wayne State University School of Medicine, Detroit, Michigan, USA. jvazquez@intmed.wayne.edu
Abstract
PURPOSE: To evaluate the efficacy of alcohol-based and alcohol-free melaleuca oral solution in patients with AIDS and fluconazole-refractory oropharyngeal candidiasis. METHOD: We performed a prospective, single-center, open-label study in a university-based inner city HIV/AIDS clinic. The study included 27 patients with AIDS and oral candidiasis clinically refractory tofluconazole. Patients were randomized 1:1 to receive either alcohol-based or alcohol-free melaleuca oral solution four times daily for 2-4 weeks. Thirteen patients were enrolled into cohort 1, and 14 patients were enrolled into cohort 2. The main outcome measure was resolution of clinical lesions of oral candidiasis. Evaluations were performed at 2 and 4 weeks for clinical signs and symptoms of oral candidiasis and quantitative yeast cultures. RESULTS: All C. albicans isolates showed some degree of in vitro resistance to fluconazole. Overall, using a modified intent-to-treat analysis, 60% of patients demonstrated a clinical response to the melaleuca oral solution (7 patients cured and 8 patients clinically improved) at the 4-week evaluation. CONCLUSION: Both formulations of the melaleuca oral solution appear to be effective alternative regimens for patients with AIDS suffering from oropharyngeal candidiasis refractory tofluconazole.
RCT Entities:
PURPOSE: To evaluate the efficacy of alcohol-based and alcohol-free melaleuca oral solution in patients with AIDS and fluconazole-refractory oropharyngeal candidiasis. METHOD: We performed a prospective, single-center, open-label study in a university-based inner city HIV/AIDS clinic. The study included 27 patients with AIDS and oral candidiasis clinically refractory to fluconazole. Patients were randomized 1:1 to receive either alcohol-based or alcohol-free melaleuca oral solution four times daily for 2-4 weeks. Thirteen patients were enrolled into cohort 1, and 14 patients were enrolled into cohort 2. The main outcome measure was resolution of clinical lesions of oral candidiasis. Evaluations were performed at 2 and 4 weeks for clinical signs and symptoms of oral candidiasis and quantitative yeast cultures. RESULTS: All C. albicans isolates showed some degree of in vitro resistance to fluconazole. Overall, using a modified intent-to-treat analysis, 60% of patients demonstrated a clinical response to the melaleuca oral solution (7 patients cured and 8 patients clinically improved) at the 4-week evaluation. CONCLUSION: Both formulations of the melaleuca oral solution appear to be effective alternative regimens for patients with AIDS suffering from oropharyngeal candidiasis refractory to fluconazole.
Authors: Gabriela Lacet Silva Ferreira; Ana Luíza Alves de Lima Pérez; Ítalo Martins Rocha; Mayara Abreu Pinheiro; Ricardo Dias de Castro; Hugo Lemes Carlo; Edeltrudes de Oliveira Lima; Lúcio Roberto Castellano Journal: Evid Based Complement Alternat Med Date: 2015-03-26 Impact factor: 2.629
Authors: Anna Mertas; Aleksandra Garbusińska; Ewelina Szliszka; Andrzej Jureczko; Magdalena Kowalska; Wojciech Król Journal: Biomed Res Int Date: 2015-02-04 Impact factor: 3.411
Authors: Elba Dos Santos Ferreira; Pedro Luiz Rosalen; Bruna Benso; Janaina de Cássia Orlandi Sardi; Carina Denny; Simone Alves de Sousa; Felipe Queiroga Sarmento Guerra; Edeltrudes de Oliveira Lima; Irlan Almeida Freires; Ricardo Dias de Castro Journal: Evid Based Complement Alternat Med Date: 2021-01-07 Impact factor: 2.629